Apr 26, 2016

Posted by in Biotech Stocks | 0 Comments

Investor’s Alert: Relypsa Inc (NASDAQ:RLYP), Rexahn Pharmaceuticals Inc (NYSEMKT:RNN), Verastem Inc (NASDAQ:VSTM)

Investor’s Alert: Relypsa Inc (NASDAQ:RLYP), Rexahn Pharmaceuticals Inc (NYSEMKT:RNN), Verastem Inc (NASDAQ:VSTM)

Relypsa Inc (NASDAQ:RLYP) stock is at $18.67, down -2.96 percent from its previous close of $19.24. The stock opened the session at $19.31 and touched its highest price point at $20.06. The company’s stock’s lowest price point for the session stood at $18.51. Its yesterday’s volume was 1.87 million shares in comparison to its usual trading volume of 3.07 million shares.

Relypsa Inc (NASDAQ:RLYP) on April 21, 2016 announced that new analyses from studies of Veltassa® (patiromer) for oral suspension will be presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings, taking place April 27-May 1 in Boston.

Veltassa was approved by the U.S. Food and Drug Administration for the treatment of hyperkalemia in the United States on October 21, 2015, becoming the first medicine in more than 50 years for people with elevated serum potassium.

Data to be presented include:

  • Results from a proof of concept study (RLY5016-201) that evaluated the effect of Veltassa on potassium and phosphate in six hyperkalemia patients on hemodialysis;
  • An analysis evaluating the effect of Veltassa on urine calcium and phosphate excretion from the Phase 1 RLY5016-101 and 102 studies in healthy adults;
  • Data from a post-hoc sub-group analysis of patients with resistant hypertension in the Phase 2 AMETHYST-DN trial, which evaluated Veltassa over 52 weeks in hyperkalemia patients with chronic kidney disease (CKD) and type 2 diabetes who were taking renin angiotensin aldosterone system (RAAS) inhibitors.

Rexahn Pharmaceuticals Inc (NYSEMKT:RNN) stock is at $0.331, up +5.08 percent from its previous close of $0.32. Its yesterday’s volume was 1.78 million shares in comparison to its usual trading volume of 370,409.00 shares. Previous 5 days graph demonstrated a positive move of 3.28%. Its quarterly performance remained red with the percentage of -5.43, while its year to date performance showed that the stock plunged overall -10.54%.

Rexahn Pharmaceuticals Inc (NYSEMKT:RNN) on April 20, 2016 announced that final data from the dose-escalation segment (Stage 1) of a Phase Ib/IIa clinical trial of Archexin® were presented at the 2016 American Association for Cancer Research Annual Meeting (AACR) in New Orleans, Louisiana.

The Phase Ib/IIa clinical trial is evaluating Archexin, in combination with everolimus (a widely used chemotherapy drug) in patients with metastatic renal cell carcinoma (mRCC).  The results were presented during the Late Breaking and Clinical Trials Session at AACR by Drs. S. Tagawa, G. Chatta, N. Agarwal and Rexahn scientists in a poster presentation entitled “Phase Ib/IIa Study of RX-0201 (Archexin®), A Novel Akt-1 Antisense Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma.”

Verastem Inc (NASDAQ:VSTM) traded in the range of $1.58 and $1.93 in its previous trading session. The stock recorded the volume of 1.78 million shares so far, in comparison its average daily trading volume of 309,261.00 shares. Company’s year to date performance remained quiet optimistic with the rise of 1.09%. The stock opened at $1.60 and its closing price for the day was $1.86, up +17.72 percent from its previous close.

Verastem Inc (NASDAQ:VSTM) on April 18, 2016 announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company’s global clinical development strategy and clinical operations. Dr. Berk replaces interim Chief Medical Officer, Lou Vaickus, MD, FACP, from aktaPD who will continue to serve Verastem as a consultant.

Verastem also announced the further strengthening of its management team through the appointment and promotion of several key individuals. Jonathan Pachter, PhD has been promoted to Chief Scientific Officer, and David Weaver, PhD has been appointed as Vice President, Translational Medicine. John “Jack” Green, has resigned as the Company’s part-time Chief Financial Officer and will continue to serve the Company as a consultant, and Joe Chiapponi, Vice President, Finance, has been named Treasurer, Principal Accounting and Financial Officer.


Comments are closed.